Therapy of low-risk subsets of childhood acute lymphoblastic leukemia: When do we say enough?

Pediatric Blood and Cancer

Volumn 45, Issue 7, 2005, Pages 876-880

  Hunger, Stephen P ^a   Winick, Naomi J ^b   Sather, Harland N ^c   Carroll, William L ^d  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPTERIN; ANTHRACYCLINE DERIVATIVE; ASPARAGINASE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILDHOOD LEUKEMIA; DRUG MEGADOSE; HUMAN; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MINIMAL RESIDUAL DISEASE; NOTE; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL TRANSPLANTATION;

CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 27644547711     PISSN: 15455009     EISSN: None     Source Type: Journal    
DOI: 10.1002/pbc.20501     Document Type: Note

References (24)

1. Kersey JH. Fifty years of the biology and therapy of childhood leukemia. Blood 1997;90:4243-4251.
2. Farber S, Diamond LK, Mercer RD, et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 1948;238:787-793.
3. Pinkel D. Five-year follow-up of "total therapy" of childhood lymphocytic leukemia. JAMA 1971;216:648-652.
4. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
5. Gaynon PS, Desai AA, Bostrom BC, et al. Early response to treatment and outcome in childhood acute lymphoblastic leukemia. Cancer 1997;80:1717-1726.
6. Szczepanski T, Orfao A, van der Velden VH, et al. Minimal residual disease in leukaemia patients. Lancet Oncol 2001;2:409-417.
7. Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003;121:823-838.
8. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310-3322.
9. Schrappe M. Evolution of BFM trials for childhood ALL. Ann Hematol 2004;83:S121-S123.
10. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versys weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: A report from the Children's Cancer Group. Blood 2003;101:3809-3817.
11. Schultz KR, Pullen J, Sather H, et al. Biology-driven classification of childhood acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2004;104:151a (abstract).
12. Chauvenet A, Martin PL, Bell B, et al. Anti-metabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: Pediatric Oncology Group (POG) study 9201. Pediatr Blood Cancer 2005;44:567 (abstract).
13. Onega JA, Nesbit ME, Donaldson MH, et al. L-Asparaginase, vincristine, and prednisone for induction of first remission in acute loymphocytic leukemia. Cancer Res 1977;37:535-540.
14. Hitchcock-Bryan S, Gelber R, Cassady JR, et al. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1986;14:211-215.
15. Riehm H, Feickert H-J, Schrappe M, et al. Therapy results in five ALL-BFM studies since 1970: Implications of risk factors for prognosis. Haematol Blood Transfus 1987;30:139-146.
16. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;12:2223-2233.
17. Maloney KW, Shuster JJ, Murphy S, et al. Long term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. Leukemia 2000;14:2276-2285.
18. Bleyer WA, Sather HN, Nickerson HJ, et al. Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: A report of the CCG-161 study by the Children's Cancer Study Group. J Clin Oncol 1991;9:1012-1021.
19. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-1548.
20. Gaynon PS, Qu RP, Chappell RJ, et al. Survival after relapse in childhood acute lymphoblastic leukemia: Impact of site and time to first relapse-The Children's Cancer Group Experience. Cancer 1998;82:1387-1395.
21. Wheeler K, Richards S, Bailey C, et al. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: The MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol 1998;101:94-103.
22. Tubergen DG, Gilchrist GS, O'Brien RT, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Childrens Cancer Group phase III trial. J Clin Oncol 11:527-537.
23. Kaspers GJ, Smets LA, Pieters R, et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: Results of an in vitro study. Blood 1995;85:751-756.
24. Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000;96:1094-1099.